Novo's Victoza hits another FDA speed bump

Novo Nordisk's diabetes drug Victoza has run into another speed bump at the FDA. The Danish biotech says that the FDA's formal feedback on the drug has been delayed beyond the end of the year. But the company adds that a response is expected in a matter of weeks. The closely-watched diabetes drug, also called liraglutide, has been approved in Europe but has faced repeated delays in the U.S.

"Formal feedback from the United States Food and Drug Administration (FDA) regarding liraglutide, a once-daily human GLP-1 analogue, is expected within weeks," Novo Nordisk says in a statement. "Novo Nordisk continues the constructive dialogue with the FDA regarding the regulatory process for liraglutide."

- read Novo's release
- here's the story from Reuters

Related Articles:
Liraglutide bests Xenical at cutting weight, blood pressure
FDA delays feedback on Novo's Victoza
Novo Nordisk predicts blockbuster diabetes drug approval